Top News

Royalty Pharma to Purchase up to $1.5 Billion of PTC Therapeutics’ Royalty on Roche’s Evrysdi

October 20, 2023

The spinal muscular atrophy treatment, currently marketed by Roche, generated $1.2 billion in sales in 2022.

Bristol Myers Squibb Acquires Mirati Therapeutics for up to $5.8 Billion

October 12, 2023

Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.

2023 Nobel Prize in Medicine Awarded for Development of mRNA Vaccines Against COVID-19

October 04, 2023

The prize was awarded jointly to Katalin Karikó and Drew Weissman for their groundbreaking discovery regarding modification of the bases in mRNA.

Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business

October 02, 2023

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

BARDA Awards Gritstone bio $433 Million Contract for Phase IIb Study of Next-Gen COVID-19 Vaccine

September 29, 2023

The contract is part of US Department of Health and Human Services’ ‘Project NextGen’ initiative, aimed at pushing forward new and stronger COVID-19 vaccines and therapies.

White House Sets Medicare Price Negotiation Targets

August 31, 2023

The Centers for Medicare & Medicaid Services (CMS) has announced the first 10 drugs covered under Medicare Part D selected for negotiation.

Danaher to Acquire Abcam in $5.7 Billion Deal

August 29, 2023

Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.

Lilly Completes Spate of Acquisitions

August 15, 2023

The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.

Novartis Finalizes Chinook Therapeutics Acquisition in Deal Worth Up to $3.5 Billion

August 11, 2023

Novartis has completed its acquisition of biopharma company Chinook Therapeutics.

Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion

August 01, 2023

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.